NCT05052567View on ClinicalTrials.gov

CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

October 21, 2021

Primary Completion Date

June 29, 2024

Study Completion Date

June 29, 2024

Conditions

Pancreatic Cancer

Interventions

DRUG

CEND-1

The dose is specified according to the protocol. CEND-1+paclitaxel (albumin-bound type)+gemcitabine

Trial Locations (1)

100039

Chinese PLA General Hospital, Beijing

Sponsors

Collaborators (1)

Cend Therapeutics Inc.

All Listed Sponsors

collaborator

Cend Therapeutics Inc.

UNKNOWN

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY